Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding event and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in ...

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced a total of 11 ...

Experts at Chapman University have developed a mobile app that needs nail pictures to detect signs of anemia, a well-known blood condition, with high accuracy.

"Glanzmann thrombasthenia is a serious and devastating bleeding disorder where patients often experience in excess of 60-80 treatment-requiring bleeds annually. These interim Phase 2 results ...

Researchers have developed 2 new predictive models using peripheral blood testing to distinguish between 2 forms of systemic mastocytosis (SM): indolent systemic mastocytosis (ISM) and advanced ...

Glanzmann thrombasthenia (GT) is a rare blood clotting disorder. It’s caused by genetic mutations that affect your platelets, and it can make you more prone to excess bleeding.

Could Collecting Period Blood Via A Menstrual Pad Offer An Alternative To Uncomfortable Pap Smears? WH spoke with the inventors hoping to disrupt health care with a potentially life-changing solve.